Видео ютуба по тегу Medicines: Astx727

NIBIT-ML1: ipilimumab and nivolumab with ASTX727 in PD-1 resistant melanoma
NIBIT-ML1: ipilimumab and nivolumab with ASTX727 in PD-1 resistant melanoma
ASTX727 + a molecularly-targeted agent as personalized maintenance therapy in patients with AML
ASTX727 + a molecularly-targeted agent as personalized maintenance therapy in patients with AML
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
Oral combination of ASTX727 (decitabine/cedazuridine) plus Ven for older/unfit patients with AML
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
10-day ASTX727 (decitabine/cedazuridine) with venetoclax in the treatment of R/R AML
Safety and efficacy of ASTX727 in patients with CMML from Phase II and Phase III ASCERTAIN studies
Safety and efficacy of ASTX727 in patients with CMML from Phase II and Phase III ASCERTAIN studies
The efficacy of low-dose ASTX727 in low-risk MDS
The efficacy of low-dose ASTX727 in low-risk MDS
Updates from a study evaluating ASTX727 + venetoclax for patients with AML
Updates from a study evaluating ASTX727 + venetoclax for patients with AML
ASTX727 plus venetoclax: Phase I study of total oral therapy for high-risk MDS/CMML
ASTX727 plus venetoclax: Phase I study of total oral therapy for high-risk MDS/CMML
Updates on a phase 2 confirmation study of oral ASTX727 in patients with MDS
Updates on a phase 2 confirmation study of oral ASTX727 in patients with MDS
Promising results in MDS for ASTX727, an oral decitabine and cytidine deaminase inhibitor agent
Promising results in MDS for ASTX727, an oral decitabine and cytidine deaminase inhibitor agent